Evoke Pharma to Report Second Quarter Results on August 10, 2022
SOLANA BEACH, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments...
Pharmaceutical
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™
Nes-Ziona, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Bavarian Nordic Enters Additional Contract with APAC Country for Supply of Smallpox/Monkeypox Vaccine in 2023
Larger order for 2023 follows initial order for supply in 2022 COPENHAGEN, Denmark, August 3, 2022 – Bavarian Nordic A/S...
Rhythm Pharmaceuticals to Present at Canaccord Genuity 42nd Annual Growth Conference
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of...
Mersana Therapeutics to Host Second Quarter 2022 Conference Call on August 8, 2022 and Present at Upcoming Conferences
CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...
Journey Medical Corporation to Announce Second Quarter 2022 Financial Results on August 9, 2022
Company to host conference call to discuss financial results and provide a corporate update on August 9, 2022 at 4:30...
CURE Pharmaceutical Announces the Appointment of New Board Member
Gerald Bagg brings deep understanding of CPG to CUREOXNARD, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp....
Y-mAbs to Announce Second Quarter 2022 Financial and Operating Results on August 8, 2022
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that...
G1 Therapeutics to Participate Virtually in the 2022 BTIG Biotechnology Conference and the 2022 Wedbush Pacgrow Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...
GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine
GreenLight Woburn lab 2 GreenLight’s messenger RNA production process is transferable to large-scale equipment and CMO facilitiesGreenLight’s messenger RNA production...
CURE Pharmaceutical Announces Teleconference With Investors
Updates on Recent Transaction and Business will be ProvidedOXNARD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp....
Nuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement
Fort Lee, NJ, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical...
Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)
Ranked #1 in IFFGD Virtual Walk to spread awareness and support research for gastrointestinal disorders Evoke attending ANMS 2022 meeting...
CorMedix Inc. To Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11
BERKELEY HEIGHTS, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal Barrier Health
New website aligns with company’s mission to become a global leader in addressing diseases linked to intestinal barrier disruption and...
CURE Pharmaceutical Announces the Sale of a Portion of its Platform Technology IP for $20 Million
Proceeds Will Be Used to Grow CURE’s Wellness and Beauty Brands and Its Remaining Proprietary Platform TechnologyOXNARD, Calif., July 28,...
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
Phase 2a trial initiation planned for the first half of 2023 subject to IND clearance and available capitalNEWTON, Mass. and...
Veru to Report Fiscal 2022 Third Quarter Financial Results, Host Conference Call on August 11th
MIAMI, July 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
Prescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023NEWTON, Mass. and GENEVA, July 28, 2022...